Afamelanotide

Afamelanotide

SCHEMBL29352792

CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MC1R

The experimentally established mechanism targets of Afamelanotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MC1R known ✓ Q01726 2/20 0.81
▸ MC4R P32245 3/20 0.81
▸ MC5R P33032 2/20 0.81
▸ MC3R P41968 2/20 0.81
▸ C5AR1 P21730 2/20 0.72
▸ IL23R Q5VWK5 3/20 0.65
▸ CTSL P07711 3/20 0.62
▸ CTSS P25774 3/20 0.62
▸ CTSK P43235 3/20 0.62
▸ CTSH P09668 1/20 0.62
▸ NMBR P28336 1/20 0.61
▸ GRPR P30550 1/20 0.61
▸ TFPI P10646 2/20 0.60
▸ CXCR4 P61073 4/20 0.60
▸ GLP1R P43220 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Afamelanotide SCHEMBL22463810 1.00 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL22463811 1.00 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL29419548 1.00 MC4R (0.81) MC4RMC5RMC3RMC1RC5AR1
Afamelanotide SCHEMBL29533175 1.00 MC4R (0.80) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL29970570 0.98 MC4R (0.77) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL18281742 0.96 MC4R (0.77) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL30312751 0.96 MC4R (0.77) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL29533782 0.96 C5AR1 (0.77) MC4RMC5RMC3RMC1RC5AR1
SCHEMBL18281737 0.96 MC4R (0.77) MC4RMC5RMC3RMC1RC5AR1
Intermedine SCHEMBL20548027 0.96 MC4R (0.82) MC4RMC5RMC3RMC1RC5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024000720-A1 METHOD AND SYSTEM FOR TOOL WEAR MONITORING UNDER VARIABLE WORKING CONDITION BASED ON CUTTING FORCE COMPONENT DECOUPLING 西安交通大学 2024-01-04 — — WO claimed
CN-114905336-B Variable working condition cutter wear monitoring method and system based on cutting force component decoupling 西安交通大学 2023-07-25 — — CN claimed
CN-116318786-A Log audit monitoring method and device 浪潮软件集团有限公司 2023-06-23 — — CN claimed
CN-115456439-A Resource environment bearing capacity monitoring and early warning system 河南省资源环境调查一院 2022-12-09 — — CN claimed
CN-114905336-A Variable working condition cutter wear monitoring method and system based on cutting force component decoupling 西安交通大学 2022-08-16 — — CN claimed
US-20220245498-A1 HYBRID QUANTUM COMPUTATION ARCHITECTURE FOR SOLVING A SYSTEM OF LINEAR BINARY RELATIONS Terra Quantum AG (CH) 2022-08-04 — — US claimed
CN-114663285-A Old film super-resolution system based on convolutional neural network 哈尔滨工业大学 2022-06-24 — — CN claimed
CN-114449532-A Secure sensing spectrum sharing method based on discrete time energy acquisition 人工智能与数字经济广东省实验室(广州) 2022-05-06 — — CN claimed
WO-2026107390-A2 METHODS AND SYSTEMS FOR PREVENTING CARDIOMETABOLIC DISEASES VALIDAE HEALTH, L.P. (US) 2026-05-21 — — WO disclosed
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS ENDEVICA BIO INC (US) 2026-04-09 — — US disclosed
US-20260000765-A1 CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS LENTIGEN TECH INC (US) 2026-01-01 — — US disclosed
US-12435377-B2 Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins THE BROAD INSTITUTE, INC. (US) 2025-10-07 — — US disclosed
EP-4605407-A2 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS Endevica Bio, Inc. (US) 2025-08-27 — — EP disclosed
CN-119961221-A Method, device and equipment for auditing configuration files based on multiple manufacturers 中盈优创资讯科技有限公司 2025-05-09 — — CN disclosed
WO-2022146509-A1 METHOD AND APPARATUS FOR DEEP NEURAL NETWORK BASED INTER-FRAME PREDICTION IN VIDEO CODING Tencent America LLC (US) 2022-07-07 — — WO disclosed
CN-114663285-A Old film super-resolution system based on convolutional neural network 哈尔滨工业大学 2022-06-24 — — CN disclosed
EP-4007951-A2 MULTI-LINGUAL LINE-OF-CODE COMPLETION SYSTEM Microsoft Technology Licensing, LLC (US) 2022-06-08 — — EP disclosed
CN-114492167-A Air conditioner cluster aggregation external characteristic modeling method based on online deep learning 武汉大学 2022-05-13 — — CN disclosed
CN-114449532-A Secure sensing spectrum sharing method based on discrete time energy acquisition 人工智能与数字经济广东省实验室(广州) 2022-05-06 — — CN disclosed
CN-113957090-A Halostachys chinensis metallothionein HcMT compound and application thereof in sunscreen cream 四川轻化工大学 2022-01-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098072-A1 METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS MC1R, MC4R, MC5R MC1R 1/4885MC4R 2/4885MC5R 3/4885
US-20260000765-A1 CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS RORC, RORB, TNFRSF9 MC1R 799/4885MC4R 1918/4885MC5R 2681/4885
US-12435377-B2 Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins GSTM2, GSTM1, AS3MT MC1R 4107/4885MC4R 4538/4885MC5R 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback